Abstract
We retrospectively investigated the ability of adalimumab (ADA) to reduce disease activity, improve physical function, and retard the progression of structural damage in 167 patients with rheumatoid arthritis. Clinicaland functional outcomes were compared between patients with or without prior biologic treatment and those with or without concomitant methotrexate (MTX) treatment. At week 52, 38.3% achieved clinical remission: 42.4 and 28.6% of patients achieved remission in those without and with previous biologics, respectively, while 42.7 and 12.5% of patients achieved remission in those with and without concomitant MTX, respectively. ADA treatment significantly reduced the rate of radiographic progression from 27.1 ± 46.0 (median 13.6; 25th-75th percentiles 8.3 to 28.9) at baseline to 0.8 ± 5.0 (median 0.0; 25th-75th percentiles -0.9 to 2.0) at week 52 (P\0.0001). Radiographic progression was absent in 59.8% of patients. Sixty adverse events (34.21/100 patient-years) were reported, 16 of which were serious (9.12/100 patient-years). ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 327-338 |
| Number of pages | 12 |
| Journal | Modern Rheumatology |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2012 Jun |
Fingerprint
Keywords
- Adalimumab
- Japanese
- Radiographic outcome
- Retrospective study
- Rheumatoid arthritis
ASJC Scopus subject areas
- Rheumatology
Cite this
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis : Retrospective analyses of data collectedduring the first year of adalimumab treatment in routine clinical practice (HARMONY study). / Takeuchi, Tsutomu; Tanaka, Yoshiya; Kaneko, Yuko; Tanaka, Eiichi; Hirata, Shintaro; Kurasawa, Takahiko; Kubo, Satoshi; Saito, Kazuyoshi; Shidara, Kumi; Kimura, Noriko; Nagasawa, Hayato; Kameda, Hideto; Amano, Koichi; Yamanaka, Hisashi.
In: Modern Rheumatology, Vol. 22, No. 3, 06.2012, p. 327-338.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis
T2 - Retrospective analyses of data collectedduring the first year of adalimumab treatment in routine clinical practice (HARMONY study)
AU - Takeuchi, Tsutomu
AU - Tanaka, Yoshiya
AU - Kaneko, Yuko
AU - Tanaka, Eiichi
AU - Hirata, Shintaro
AU - Kurasawa, Takahiko
AU - Kubo, Satoshi
AU - Saito, Kazuyoshi
AU - Shidara, Kumi
AU - Kimura, Noriko
AU - Nagasawa, Hayato
AU - Kameda, Hideto
AU - Amano, Koichi
AU - Yamanaka, Hisashi
PY - 2012/6
Y1 - 2012/6
N2 - We retrospectively investigated the ability of adalimumab (ADA) to reduce disease activity, improve physical function, and retard the progression of structural damage in 167 patients with rheumatoid arthritis. Clinicaland functional outcomes were compared between patients with or without prior biologic treatment and those with or without concomitant methotrexate (MTX) treatment. At week 52, 38.3% achieved clinical remission: 42.4 and 28.6% of patients achieved remission in those without and with previous biologics, respectively, while 42.7 and 12.5% of patients achieved remission in those with and without concomitant MTX, respectively. ADA treatment significantly reduced the rate of radiographic progression from 27.1 ± 46.0 (median 13.6; 25th-75th percentiles 8.3 to 28.9) at baseline to 0.8 ± 5.0 (median 0.0; 25th-75th percentiles -0.9 to 2.0) at week 52 (P\0.0001). Radiographic progression was absent in 59.8% of patients. Sixty adverse events (34.21/100 patient-years) were reported, 16 of which were serious (9.12/100 patient-years). ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice.
AB - We retrospectively investigated the ability of adalimumab (ADA) to reduce disease activity, improve physical function, and retard the progression of structural damage in 167 patients with rheumatoid arthritis. Clinicaland functional outcomes were compared between patients with or without prior biologic treatment and those with or without concomitant methotrexate (MTX) treatment. At week 52, 38.3% achieved clinical remission: 42.4 and 28.6% of patients achieved remission in those without and with previous biologics, respectively, while 42.7 and 12.5% of patients achieved remission in those with and without concomitant MTX, respectively. ADA treatment significantly reduced the rate of radiographic progression from 27.1 ± 46.0 (median 13.6; 25th-75th percentiles 8.3 to 28.9) at baseline to 0.8 ± 5.0 (median 0.0; 25th-75th percentiles -0.9 to 2.0) at week 52 (P\0.0001). Radiographic progression was absent in 59.8% of patients. Sixty adverse events (34.21/100 patient-years) were reported, 16 of which were serious (9.12/100 patient-years). ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice.
KW - Adalimumab
KW - Japanese
KW - Radiographic outcome
KW - Retrospective study
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84865372548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865372548&partnerID=8YFLogxK
U2 - 10.1007/s10165-011-0516-6
DO - 10.1007/s10165-011-0516-6
M3 - Article
VL - 22
SP - 327
EP - 338
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 3
ER -